Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBRSWJ)

Drug Name
Natrunix Drug Info
Indication
Disease Entry ICD 11 Status REF
Arthritis FA20 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMBRSWJ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-1 alpha (IL1A) TTPM6HI IL1A_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-1 alpha (IL1A) DTT IL1A 4.626 4.89 5.338 5.448
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-1 alpha (IL1A) DTT IL1A 7.52E-01 1.41E-02 0.09
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05363917) Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis. U.S.National Institutes of Health.